PRISM Mid-Day Movers: Biotech and MedDevices are Leading Today’s Index’s.
Quince Therapeutics Inc. (Nasdaq: QNCX) remains a standout mover, holding onto a two‑day surge that keeps it among the top leaders in its rare‑disease and emerging‑biotech index for a second straight session. Shares are still up roughly 63% today and trading around 1.95 dollars with a market capitalization of about 105 million dollars, nearly doubling from their 1.04‑dollar level at the start of 2024 as traders crowd into this thinly traded name. The sustained momentum reflects growing speculative interest in Quince’s business model of acquiring and in‑licensing clinical‑stage rare‑disease assets, alongside out‑licensing potential for its bone‑targeting platform centered on NOV004, an anabolic peptide designed to home to fracture sites and drive rapid gains in bone density and strength in preclinical studies.
Neuronetics Inc. (NASDAQ: STIM) is having a strong session, with the stock up about 39% as it jumps into the high‑1‑dollar range on a pickup in trading activity versus its typical volume. Even after today’s surge, the commercial‑stage neurostimulation company remains nearly 50% below its 2.75‑dollar level from the start of 2024, leaving the market capitalization around 95 million dollars. The move highlights renewed speculative interest in Neuronetics’ NeuroStar Advanced Therapy System, a non‑invasive transcranial magnetic stimulation platform for treatment‑resistant major depressive disorder, where growing adoption in psychiatric practices can create operating leverage in what is still a small‑cap, high‑volatility med‑tech story.
Other Notable Movers:
AYR Wellness Inc. (AYRWF) up 17%
Nektar Therapeutics (NKTR) up 17%
Insight Molecular Diagnostics (IMDX) down -29%
